Global Bovine Mastitis Market is segmented By Type (Clinical Mastitis, Sub-Clinical Mastitis), By Treatment Type (Antibiotics, Surgery, Vaccines, Pain Killers, Others), By Route of Administration (Intra-Mammary and Systemic), By Therapy (Lactating Period, Dry Period), By End-user (Hospitals and Clinics, Veterinary Centers, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2023-2030
Bovine Mastitis Market Overview
The Global "Bovine Mastitis Market" is estimated to reach at a CAGR of 5.1% during the forecast period (2023-2030).
Bovine mastitis is inflammation of the mammary gland, the most prevalent disease in dairy cattle.
Bovine Mastitis Market Scope
|
Metrics |
Details |
|
Market CAGR |
5.1% |
|
Segments Covered |
By Type, By Treatment Type, By Route of Administration, By Therapy, By End-user, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
To Know More Insights - Download Sample
Bovine Mastitis Market Dynamics
The launch of new guidelines for successful dry periods of dairy cows is expected to drive the market's growth.
According to the news article published on 11 August 2020, European experts have agreed on a common approach to promoting a healthy dry period by curing existing and avoiding new intramammary infections (IMI) while considering prudent use of antimicrobials. In 2019, DeLaval called selected European experts to Hamra Farm in Sweden to address drying-off strategies. During the meeting, the associates shared their expertise and discussed differences in farm management and practical recommendation between countries. Based on this input, a new guideline for a successful dry period was launched. It included maintaining properly functioning milking equipment, dipping teats at the end of the milking procedures and keeping accurate and consistent mastitis records; treatment decisions are all important measures during lactation.
Moreover, a thorough udder and overall health program, including trimming tails, flaming udders, trimming feet, applying parasiticides, and maintaining an acceptable body condition score (BCS), is equally important. Thus, from the above statements.
Financial losses attributed to mastitis are expected to hamper the market's growth.
The market is expected to drive in the forecast period.
According to the research article, in September 2020. They conducted a study to evaluate and quantify the different factors affecting mastitis costs in cattle to quantify the annual and monthly financial losses. Mastitis was present in 57.1% of cows, while clinical mastitis (CM) was 19%. The geometric mean of SCC/ml in bulk tank milk samples of 150 cattle dairy farms was 556.3×103. The annual subclinical mastitis (SCM)-the related economic loss was 21,933,258.6 LE. The two most important cost segments were the subsequent decrease in milk Treatment Typeion and quality premium losses. The quality premium loss was 1,369,602.1 LE.
Moreover, the annual economic loss due to decreased milk Treatment Typeion resulting from SCM was 20,563,656.5 LE. The total cost of 80 CM cases, including the failure and preventive costs, was 1,196,871.4 LE, including 1,169,150.4 LE failure costs and 27,721.0 LE preventive costs. The average cost per CM case was 28,760.9 LE, including veterinary time and consultation fees of 250.0 LE, labor 562.5 LE, premature culling 736,000.0 LE, decreased milk Treatment Typeion 4085.18 LE (13.7%), discarded milk 185.3 LE (1%), and drugs and treatments 328.9 LE (1%). Thus, from the above statements, the market is expected to hamper in the forecast period.
COVID-19 Impact Analysis
COVID-19 has did not significantly impact the market of bovine mastitis. However, the pandemic is interrupting the medical supply chain, and social distancing has created problems regarding the availability of medicines due to reduced operations in veterinary pharmacies. Moreover, the demand for dairy Treatment Types has increased despite lockdown and social distancing measures during the pandemic. These goods fall under the essential Treatment Types category; therefore, the market is expected to rise significantly in the forecast period.
Bovine Mastitis Market Segment Analysis
The clinical Mastitis segment is expected to hold the largest market share in this market segment.
The clinical mastitis segment accounted for the largest market share in 2020. The segment growth is attributed to the increase in the dairy herd size; raising incidence cases of clinical mastitis in dairy cattle farms is expected to boost the market in the forecast period. For instance, According to the article, on 14 October 2020. They have conducted a study on a large commercial dairy farm with almost 2500 Holstein cows. Data were collected from 2014 to 2018 and involved 9663 calving records for 4256 cows. The incidence rate on the farm was 21.9% for clinical mastitis, and the prevalence rate for clinical mastitis is 28.0%. Of the 5148 cows, clinical mastitis happened most often; the number of days (± standard deviation) from calving to disease occurrence for clinical mastitis was 115.2 ± 101.0. Moreover, it occurred during all stages of Treatment Typeion. Therefore, results showed that clinical mastitis occurred most often in this temperate zone.
In addition, the urgent need for treatment of clinical mastitis, combined with the availability of drugs and growing awareness globally, is expected to hold the largest market share in the forecast period from the above statements.
The intra-Mammary segment is expected to hold the largest market share in this market segment.
The intra- mammary segment accounted for the largest market share in 2020. According to Hindawi, on 3 March 2019, Mastitis in dairy cattle is a highly prevalent infectious disease. They have conducted a study using Angelica dahurica and Rheum officinale extracts (designated as Yi-Xiong-Tang, YXT) for mastitis treatment. California mastitis test (CMT) was performed, and 67 mastitis udder quarters are identified among 179 lactating dairy cows. These 67 mastitis udder quarters were subjected to treatments by intramammary infusion of YXT twice a day for three consecutive days. The mastitis indicators, including clots, lactate dehydrogenase (LDH), TNF-α, IL-6, IL-8, and total viable count of bacteria (TVC) in milk, were examined before and after the YXT treatment to evaluate its effectiveness. Levels of mastitis indicators from mastitis udder quarters were elevated. After YXT treatment, normal levels of these indicators were restored: TVC, 2.10 × 104 – 9.20 × 106 CFU/mL; clots, 6.56 ± 0.43 mg/mL; LDH, 181.0 ± 18.55 U/L; TNF-α, 0.02 ± 0.02 ng/mL; IL-6, 41.4 ± 11.46 pg/mL; and IL-8, 1.85 ± 0.60 pg/mL. Thus, compared with antibiotic therapy, YXT treatment has a shorter course and might have a lower probability for the causative agents to develop drug resistance because YXT is a cocktail containing multiple active ingredients, which is expected to hold the largest market segment in the forecast period.
Bovine Mastitis Market Geographical Share
North America region holds the largest market share in the global bovine mastitis market.
North America dominated the market and accounted for the largest revenue share in 2020. The region's growth is attributed to the strong adoption of intra-mammary infusion Treatment Types for the treatment, for instance, according to the article on July 27, 2020. The teat disinfection, antibiotic therapy, and culling of chronically infected cows have led to significant progress in controlling infectious mastitis pathogens such as Streptococcus agalactiae and Staphylococcus aureus. However, these methods are much less effective against environmental pathogens, particularly Streptococcus uberis and E. coli which accounts for a significant balance of subclinical and clinical mastitis in lactating and nonlactating cows and heifers. Moreover, The National Mastitis Council developed a 5-point mastitis control program in 1969 to control the incidence rate of mastitis. This 5-point mastitis control program includes dipping teats in an antiseptic solution before and after milking, proper cleaning and maintenance of milking equipment, early detection and treatment of infected animals, dry cow therapy with long-acting antibiotics to reduce the duration of existing infection and to prevent new intramammary infection, and finally culling chronically infected animals.
In addition, the presence of leading players in the region offering a wide range of Treatment Types to control the infection is expected to boost the market in the forecast period. Moreover, large-scale enterprises in North America, advanced animal healthcare infrastructure, increased investments in research and development, and increased incidences of bovine mastitis are expected to hold the largest market share in the North American region.
Bovine Mastitis Market Companies
The bovine mastitis market is vast with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Zoetis Inc., Merck & Co., Inc., Boehringer Ingelheim International GmbH, Ceva, West Way Health, Elanco and Bayer AG. The major players are adopting several growth strategies such as Treatment Type launches, acquisitions, and collaborations, which are contributing to the growth of the bovine mastitis market globally. Moreover, In April 2021, Boehringer Ingelheim announced its internal tea sealant Ubroseal to Ubroseal Blue to prevent new intramammary infections during the dry period.
Bovine Mastitis Market Key Companies to Watch
Zoetis Inc.:
Overview:
Zoetis is a global animal health company focused on discovering, developing, manufacturing, and commercialization of medicines, vaccines, diagnostic Treatment Types, biodevices, genetic tests, and precision livestock farming technology. The Company has a business, commercializing Treatment Types across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, swine, poultry, fish and sheep (collectively, livestock); and within Treatment Type categories such as vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical Treatment Types, medicated feed additives and animal health diagnostics.
Treatment Type Portfolio:
Zoetis has continuously set new standards for the manufacturing of the bovine mastitis Treatment Types including Factrel® (gonadorelin hydrochloride), Lutalyse® Injection (dinoprost tromethamine injection), Spectramast® DC (ceftiofur hydrochloride) and Spectramast® LC (ceftiofur hydrochloride).
The global bovine mastitis market report would provide an access to an approx.62 market data tables, 66 figures and 180 pages.
